Navigation Links
Four-Drug AIDS Treatment Regimen Deemed Of No Use

The inclusion of a fourth drug to the usual three-drug HIV treatment regimen is not warranted, according to researchers. The fourth drug did not reduce the HIV load// or the drug resistance, the new study said. It is published in the August 16 issue of JAMA, a theme issue on HIV/AIDS.

Roy M. Gulick, M.D., M.P.H., of Weill Medical College of Cornell University, New York, presented the findings of the study today at a JAMA media briefing at the International AIDS Conference in Toronto.

The current standard of care for initial treatment of human immunodeficiency virus 1 (HIV-1) infection is a three-drug antiretroviral regimen, which can suppress viremia (presence of HIV in the blood), increase CD4 cell counts, delay clinical progression, and improve survival, according to background information in the article. Some researchers have suggested that adding drugs to the 3-drug regimens could improve antiretroviral activity. However, additional drugs increase complexity, the potential for toxicity, and costs, and prior studies comparing 3- and 4-drug antiretroviral regimens have shown inconsistent results.

Dr. Gulick and colleagues conducted a study to determine whether a 4-drug regimen would demonstrate better antiretroviral activity than the standard 3-drug regimen. The AIDS Clinical Trials Group (ACTG) A5095 study included 765 HIV-1–infected patients who had not previously received treatment for HIV-1. The trial was a randomized, double-blind, placebo-controlled study, with enrollment and follow-up conducted from March 2001 to March 2005. The study participants received either the medications zidovudine/lamivudine plus efavirenz (3-drug regimen) or zidovudine/lamivudine/abacavir plus efavirenz (4-drug regimen).

Overall, 26 percent of 382 patients receiving the 3-drug regimen and 25 percent of 383 receiving the 4-drug regimen reached protocol-defined virologic failure; time to first virologic failure was not significantly di fferent between the two study treatment groups. In subgroup analyses, increased risk for virologic failure was seen in non-Hispanic black patients. At 3 years, the HIV-1 RNA level was less than 200 copies/mL in 90 percent of 169 and 92 percent of 156 patients receiving the 3-drug and 4-drug regimens, respectively, and less than 50 copies/mL in 85 percent of 169 and 88 percent of 156 patients.

"We found no significant differences over 3 years between the standard 3-drug regimen of zidovudine/lamivudine plus efavirenz and the 4-drug regimen of zidovudine/lamivudine/abacavir plus efavirenz for the initial treatment of HIV-1 infection with regard to initial virologic response, time to virologic failure, CD4 cell count, adverse events, adherence, resistance mutations at virologic failure, or treatment or study discontinuation rates," the authors write.

"High rates of virologic suppression achieved in this study support current guidelines that recommend 2 nucleosides plus efavirenz among preferred regimens for the initial treatment of HIV-1 infection. Adding abacavir as a fourth drug to the standard initial 3-drug regimen did not change toxicity or adherence but provided no additional benefit," the researchers conclude.

Source: Eurekalert
'"/>




Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/15/2017)... ... 2017 , ... The JPR Group, a public relations and ... will be assisting HackensackUMC Mountainside with its public relations efforts, effective January 2017. ... towns. The firm will be working closely with HackensackUMC Mountainside’s internal marketing operations. ...
(Date:1/14/2017)... ... January 14, 2017 , ... AgileMinder develops innovative products ... The Emoji Scale is now available on Apple as a fun, free emoji sticker ... by choosing one of the ten color coded values on The Emoji Scale. ...
(Date:1/13/2017)... Madrid, Spain (PRWEB) , ... January 13, 2017 , ... ... the Melia Avenida America hotel on March 3-4, 2017. This Congress is expertly ... focused on the management of patients with lung cancer. , Chaired by Dr. Giorgio ...
(Date:1/13/2017)... ... January 13, 2017 , ... ... has taken on the challenge of providing additional organic alternatives for customers who ... launch of the brand’s new line of all-natural activated charcoal products, Moody Zook ...
(Date:1/13/2017)... ... , ... People who have sensitive teeth are about as common as those ... Sadly, most dental hygiene products in the market contain chemical ingredients that only aggravate ... their daily oral care routine to keep their teeth white and healthy is a ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... , January 16, 2017 Bill is ... number of general management and leadership positions with global medical device ... a strong track record of launching new products and building successful ... , Africa and North ... ...
(Date:1/16/2017)... -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is pleased to announce ... to its Board of Directors. He is the President ... LLC . He is also the Chief Investment Officer ... firm with over $1.5 billion under management. ... analysis and portfolio management. He began his career in ...
(Date:1/15/2017)... , Jan. 14, 2017 ImmersiveTouch Inc., ... for surgeons, today announced recent appointments strengthening their Executive ... James Bowman as Chief Executive Officer, Jay ... as Vice President of Sales and Jia ... Mr. Bowman has 20 ...
Breaking Medicine Technology: